| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
From the Department of Cancer Biology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas
We determined the molecular mechanisms that regulate the pathogenesis of malignant pleural effusion (PE) associated with advanced stage of human, non-small-cell lung cancer. Intravenous injection of human PC14 and PC14PE6 (adenocarcinoma) or H226 (squamous cell carcinoma) cells into nude mice yielded numerous lung lesions. PC14 and PC14PE6 lung lesions invaded the pleura and produced PE containing a high level of vascular endothelial growth factor (VEGF)-localized vascular hyperpermeability. Lung lesions produced by H226 cells were confined to the lung parenchyma with no PE. The level of expression of VEGF mRNA and protein by the cell lines directly correlated with extent of PE formation. Transfection of PC14PE6 cells with antisense VEGF165 gene did not inhibit invasion into the pleural space but reduced PE formation. H226 cells transfected with either sense VEGF 165 or sense VEGF 121 genes induced localized vascular hyperpermeability and produced PE only after direct implantation into the thoracic cavity. The production of PE was thus associated with the ability of tumor cells to invade the pleura, a property associated with expression of high levels of urokinase-type plasminogen activator and low levels of TIMP-2. Collectively, the data demonstrate that the production of malignant PE requires tumor cells to invade the pleura and express high levels of VEGF/VPF.
This article has been cited by other articles:
 |
|
 |
|
  G. T. Stathopoulos, C. Moschos, H. Loutrari, A. Kollintza, I. Psallidas, S. Karabela, S. Magkouta, Z. Zhou, S. A. Papiris, C. Roussos, et al. Zoledronic Acid Is Effective against Experimental Malignant Pleural Effusion Am. J. Respir. Crit. Care Med., July 1, 2008; 178(1): 50 - 59. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Chetty, S. S. Lakka, P. Bhoopathi, S. Kunigal, R. Geiss, and J. S. Rao Tissue Inhibitor of Metalloproteinase 3 Suppresses Tumor Angiogenesis in Matrix Metalloproteinase 2-Down-regulated Lung Cancer Cancer Res., June 15, 2008; 68(12): 4736 - 4745. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. T. Stathopoulos, A. Kollintza, C. Moschos, I. Psallidas, T. P. Sherrill, E. N. Pitsinos, S. Vassiliou, M. Karatza, S. A. Papiris, D. Graf, et al. Tumor Necrosis Factor-{alpha} Promotes Malignant Pleural Effusion Cancer Res., October 15, 2007; 67(20): 9825 - 9834. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q. Li, S. Yano, H. Ogino, W. Wang, H. Uehara, Y. Nishioka, and S. Sone The Therapeutic Efficacy of Anti Vascular Endothelial Growth Factor Antibody, Bevacizumab, and Pemetrexed against Orthotopically Implanted Human Pleural Mesothelioma Cells in Severe Combined Immunodeficient Mice Clin. Cancer Res., October 1, 2007; 13(19): 5918 - 5925. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Sandler Bevacizumab in Non Small Cell Lung Cancer Clin. Cancer Res., August 1, 2007; 13(15): 4613s - 4616s. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Kalomenidis, A. Kollintza, I. Sigala, A. Papapetropoulos, S. Papiris, R. W. Light, and C. Roussos Angiopoietin-2 Levels Are Elevated in Exudative Pleural Effusions Chest, May 1, 2006; 129(5): 1259 - 1266. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. T. Stathopoulos, Z. Zhu, M. B. Everhart, I. Kalomenidis, W. E. Lawson, S. Bilaceroglu, T. E. Peterson, D. Mitchell, F. E. Yull, R. W. Light, et al. Nuclear Factor-{kappa}B Affects Tumor Progression in a Mouse Model of Malignant Pleural Effusion Am. J. Respir. Cell Mol. Biol., February 1, 2006; 34(2): 142 - 150. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Yano, H. Muguruma, Y. Matsumori, H. Goto, E. Nakataki, N. Edakuni, H. Tomimoto, S. Kakiuchi, A. Yamamoto, H. Uehara, et al. Antitumor Vascular Strategy for Controlling Experimental Metastatic Spread of Human Small-Cell Lung Cancer Cells with ZD6474 in Natural Killer Cell-Depleted Severe Combined Immunodeficient Mice Clin. Cancer Res., December 15, 2005; 11(24): 8789 - 8798. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. B. Guo, I. Kalomenidis, M. Hawthorne, K. S. Parman, K. B. Lane, and R. W. Light Pleurodesis Is Inhibited by Anti-Vascular Endothelial Growth Factor Antibody Chest, September 1, 2005; 128(3): 1790 - 1797. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Goto, S. Yano, Y. Matsumori, H. Ogawa, D. C. Blakey, and S. Sone Sensitization of Tumor-Associated Endothelial Cell Apoptosis by the Novel Vascular-Targeting Agent ZD6126 in Combination with Cisplatin Clin. Cancer Res., November 15, 2004; 10(22): 7671 - 7676. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Shiraga, S. Yano, A. Yamamoto, H. Ogawa, H. Goto, T. Miki, K. Miki, H. Zhang, and S. Sone Organ Heterogeneity of Host-derived Matrix Metalloproteinase Expression and Its Involvement in Multiple-Organ Metastasis by Lung Cancer Cell Lines Cancer Res., October 15, 2002; 62(20): 5967 - 5973. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Goto, S. Yano, H. Zhang, Y. Matsumori, H. Ogawa, D. C. Blakey, and S. Sone Activity of a New Vascular Targeting Agent, ZD6126, in Pulmonary Metastases by Human Lung Adenocarcinoma in Nude Mice Cancer Res., July 1, 2002; 62(13): 3711 - 3715. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Fan, S. Yano, H. Shinohara, C. Solorzano, M. Van Arsdall, C. D. Bucana, S. Pathak, E. Kruzel, R. S. Herbst, A. Onn, et al. Targeted Therapy against Human Lung Cancer in Nude Mice by High-Affinity Recombinant Antimesothelin Single-Chain Fv Immunotoxin Mol. Cancer Ther., June 1, 2002; 1(8): 595 - 600. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. C. G. LEE, D. MELKERNEKER, P. J. THOMPSON, R. W. LIGHT, and K. B. LANE Transforming Growth Factor beta Induces Vascular Endothelial Growth Factor Elaboration from Pleural Mesothelial Cells in Vivo and in Vitro Am. J. Respir. Crit. Care Med., January 1, 2002; 165(1): 88 - 94. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
